Scan how STERIS finances its growth compared with a curated peer set by reviewing list of solid balance sheet and fundamentals (24 results) across healthcare and adjacent sectors.
To own STERIS, you need to be comfortable with a healthcare equipment and services business that leans heavily on recurring chemistries and sterilization services, while funding large projects like the North Carolina chemistries build out. The recent earnings update aligns with this picture, and the new shelf registration and credit facilities do not materially alter the near term operating story.
The short term swing factor still looks like execution on capex projects and the Xodus Medical acquisition, which ties into integration risk and return on invested capital. The biggest risk remains margin pressure if tariffs, restructuring charges and higher interest costs from new debt outpace pricing and efficiency gains.
The most relevant fresh disclosure for this setup is the new US$1,600 million revolving credit facility with up to US$800 million of potential expansion plus the US$500 million delayed draw term loan linked to the Xodus Medical deal. This sits alongside the omnibus shelf that covers ordinary shares, preferreds, debt, warrants and units.
For you as a shareholder, that financing toolkit matters because the analyst consensus Narrative on Simply Wall St builds on large chemistry and sterility projects as key catalysts. The new facilities and shelf registration give STERIS room to fund acquisitions and capex, but they also raise the stakes on leverage limits, interest coverage and delivering the returns needed to justify extra capital.
Analysts are currently modeling STERIS to generate about US$7.6b in revenue and US$1.1b in earnings by 2029. This implies roughly 7.0% yearly revenue growth and an earnings increase of about US$273.1m from the current US$826.9m level.
Uncover why STERIS' fair value appears to be generally in line with its current price.
Two fair value estimates from the Simply Wall St Community cluster between about US$205 and US$271, which already shows how far views on STERIS can stretch. Some members focus on the new shelf registration and expanded credit lines as future growth fuel, while others concentrate on tariff costs and project execution risk. Expect opinions to differ widely and use that spread to test your own view against multiple alternative takes.
Explore another STERIS fair value estimate, including one that suggests it could be worth as much as $270.71.
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
If STERIS has sharpened your thinking on quality, balance sheets and long term earnings power, it can help to line that view up against other listed businesses using the Simply Wall St Screener.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com